

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Jean-Paul Cassart et al.

Serial No.: 10/650,608

Art Unit: 1642

Filing Date: August 28, 2003

Examiner: Min-Tam Davis

For: Tumour Specific animal Proteins

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

☒ Copies of the references are enclosed

☐ Copies of the references were submitted in parent application Serial No. _____.
(37 CFR 1.98(d))

☐ A copy of the International Search Report which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:

- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311,

whichever occurs first.

☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. **[or]**
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,

/Eric J. Kron/
Eric J. Kron
Attorney of Record
Registration No. 45,941

Date: August 30, 2006
Customer No. 23347
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-8961
Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				SERIAL NO.		10/650,608	
				FILING DATE		August 28, 2003	
				APPLICANT		Cassart et al.	
				GROUP		1642	
				EXAMINER		Min-Tam Davis	
				ATTORNEY DOCKET NO.		BC45300-1US	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	1.	BANERJEA et al., Colorectal cancers with microsatellite instability display mRNA expression signatures characteristic of increased immunogenicity, <i>Molecular Cancer</i> 3 :31 (2004).					
	2.	CUI et al., Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability, <i>Nature Medicine</i> 4(11) :1276 (1998).					
	3.	GUILLEMOT et al., Essential role of <i>Mash-2</i> in extraembryonic development, <i>Nature</i> 371 :333 (1994).					
	4.	JIANG et al., Hypoxia Prevents Induction of Aromatase Expression in Human Trophoblast Cells in Culture: Potential Inhibitory Role of Hypoxia-Inducible Transcription Factor Mash-2 (Mammalian Achaete-Scute Homologous Protein-2), <i>Molecular Endocrinology</i> 14(10) :1661 (2000).					
	5.	JIANG and MENDELSON, USF1 and USF2 Mediate Inhibition of Human Trophoblast Differentiation and <i>CYP19</i> Gene Expression by Mash-2 and Hypoxia, <i>Molecular and Cellular Biology</i> , 23(17) :6117 (2003).					
	6.	JIANG and MENDELSON, O ₂ Enhancement of Human Trophoblast Differentiation and <i>hCYP19</i> (Aromatase) Gene Expression are Mediated by Proteasomal Degradation of USF1 and USF2, <i>Molecular and Cellular Biology</i> , 25(20) : 8824 (2005).					
	7.	JUBB et al., Achaete-scute like 2 (asc12) is a target of Wnt signaling and is upregulated in intestinal neoplasia, <i>Oncogene</i> 25 :3445 (2006).					
	8.	KOIDE et al., The Expression of Proprotein convertase PACE4 Is Highly Regulated by Hash-2 in Placenta: Possible Role of Placenta-Specific Basic Helix-Loop-Helix Transcription Factor, Human Achaete-Scute Homologue-2, <i>J. Biochem</i> 134 :433 (2003).					
	9.	MASSARI and MURRE, Helix-Loop-Helix Proteins: Regulators of Transcription in Eucaryotic Organisms, <i>Molecular and Cellular Biology</i> 20(2) :429 (2000).					
	10.	MIYAMOTO et al., The Human <i>ASCL2</i> Gene Escaping Genomic Imprinting and Its Expression Pattern, <i>J. of Assisted Reproduction and Genetics</i> , 19(5) : 240 (2002).					
	11.	SPINK et al., Structural basis of the Axin-adenomatous polyposis coli interaction, <i>The EMBO Journal</i> 19(10) :2270 (2000).					
	12.	WESTERMAN et al., The Human Achaete Scute Homolog 2 Gene Contains Two Promoters, Generating Overlapping Transcripts and Encoding Two Proteins with Different Nuclear Localization, <i>Placenta</i> 22 :511 (2001).					
	13.	ZHANG et al., JMJD2A Is a Novel N-CoR-Interacting Protein and Is Involved in Repression of the Human Transcription Factor Achaete Scute-Like Homologue 2 (ASCL2/Hash2), <i>Molecular and Cellular Biology</i> 25(15) :6404 (2005).					
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							